PROGRESSION OF SERUM MARKERS IN CHRONIC LIVER DISEASE PRODUCED BY CHRONIC VIRAL HEPATITIS B, C AND CO-INFECTION

Aamir Nazir, Alruba Taimoor, Raisa Naz, Sadaf Anwar Qureshi

Abstract


Background: Chronic liver disease represents a major cause of morbidity and mortality worldwide. The objectives of the study were to determine and compare values of serum markers in subgroups; category-wise (MCTP scoring system) as well as infection-wise among patients of HBV, HBC and co-infections.
Material & Methods: A cross-sectional study was conducted in the Department of Medicine, Lahore General Hospital, Lahore in 2010. Sample size was patients of chronic HBV, HCV, and co-infections. The patients were grouped with 25 subjects each in HB, HC and co-infection. Non-probability-convenience sampling was used for data collection. Demographic variables were sex and age in years. Research variables were AST/ALT ratio, prothrombin time, platelet conunt, serum albumin and serum bilirubin. Continuous variables like biochemical markers were analyzed as mean ±standard deviation (±SD) whereas categorical variables were analyzed as count and percentages using SPSS version 20.0. One-way ANOVA was applied to observe group mean differences.
Results: Out of the 75 subjects, 51(68.0%) were males and 24(32.0%) were females. The mean ±SD age was 44.69 ±7.423 years. There was a significant difference in AST/ALT ratio in chronic HBV group only (p <0.05). Platelet count significantly decreased in co-infection group only from (MCTP) class A-D (p<0.05). PT and serum bilirubin significantly increased, while serum albumin significantly decreased in all groups from MCTP class A-D (p<0.05). In class wise comparison amongst all groups, none of the biochemical markers was statistically different (p>0.05).
Conclusion: There was statistically significant differences of the values of serum markers among subgroups category-wise A-D (MCTP classes) of chronic liver disease produced by chronic HBV, HCV, and co-infection. There was no statistically significant difference of these values between subgroups infection-wise.

Keywords


chronic liver disease; viral hepatitis; serum markers; modified Child-Turcotte-Pugh score.

Full Text:

PDF

References


Lin S, Zhang YJ. Interference of apoptosis by hepatitis B virus. Viruses 2017: 9; 230.

Baig S, Siddiqui AA, Ahmed W, Qureshi H, Arif A. The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virol J 2007; 4: 128.

Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and thew outcome of hepatitis C virus infection. Ann Rev Microbiol 2004; 58: 391-424.

Vince A. Hepatitis B and C: natural course of disease. Acta Med Croatica 2005; 59: 389-92.

Bukhtiari N, Hussain T, Iqbal M, Malik AM, Qureshi AH, Hussain A. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003; 53: 136-40.

Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512-20.

Johnston DE. Special considerations in interpreting liver function tests. American Family Physician. Am Academy of Family Physicians 1999; 59: 2223-31.

Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Can Medl Assoc J 2005; 172: 367.

Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic Hepatitis C patients in clinical practice. J Clin Gastroenterol 2006; 40: 521-7.

Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

Huo TL, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl 2006; 12: 65-71.

Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2001; 96: 918-9.

Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T et al. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci 2007; 1: 1-6.

Afyon M, Artuk C, Yenilmez E, Simsek B, Kaya A. The value of indirect serum markers in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus infection. Med- Science 2017; 6: 189-94.

Mano Y, Tsukada H, kurihara T, Nomura M, Yokogawa K, Miyamoto K. Development of dosage design of hepatic metabolizing drugs using serum albumin level in chronic hepatic failure. Biol Pharm Bull 2009; 29: 1692-9.


Refbacks

  • There are currently no refbacks.


© 2011 Gomal Journal of Medical Sciences